Trametinib dimethyl sulfoxide

Pasithea Therapeutics Corp. (Nasdaq: KTTA), headquartered in Miami, Florida, has announced receipt of FDA Fast Track Designation for PAS-004, a macrocyclic small-molecule MEK inhibitor, for the treatment of neurofibromatosis type 1 (NF1)-associated plexiform neurofibromas (PN) causing significant morbidity. The designation, which enables rolling review and more frequent FDA interactions during development, is the first expedited status awarded to PAS-004 according to available source material. Plexiform neurofibromas arise from the nerve sheath and can involve multiple nerve branches simultaneously, affecting between 30% and 50% of patients with NF1. The tumors carry a risk of malignant transformation and can compress vital structures, producing morbidity that extends beyond tumor volume to include pain, functional impairment, and psychosocial burden. Surgery is not consistently viable: tumors are frequently inoperable, incompletely resectable, or recurrent, leaving systemic therapy as the primary management option for a substantial proportion of patients. MEK inhibition has been the central pharmacological strategy in this setting since selumetinib demonstrated tumor volume reduction in pediatric NF1-PN, leading to its FDA approval in 2020. However, data from adult populations remain limited, and case-based observations have described rapid regrowth following MEK inhibitor interruption, raising questions about durability and the consequences of treatment discontinuation. Qualitative research in adult NF1 populations has documented broad life impacts — including effects on appearance, independence, and role functioning — that go beyond what radiographic response measures capture, pointing to gaps in how existing therapies translate to patient-centered outcomes. PAS-004 targets MEK1/2 within the RAS-MAPK pathway and is structurally distinguished from earlier-generation inhibitors by its macrocyclic architecture. The company positions this design as potentially conferring improved selectivity or tolerability relative to linear MEK inhibitors. Phase I data released in November 2025, from a dose-escalation study in patients with MAPK pathway-driven advanced solid tumors (NCT06299839), reported a 42.8% disease control rate across 21 evaluable patients, including a confirmed partial response in a patient previously treated with a MEK inhibitor. All treatment-related adverse events were Grade 1 or 2, and the dataset included no ocular or retinal abnormalities — toxicities associated with approved MEK inhibitors such as trametinib and selumetinib. Among patients with BRAF-mutated tumors, the disease control rate reached 71.4% in efficacy-evaluable patients, though these are early-phase, non-randomized observations. The NF1-specific program is now enrolling adults in a Phase I/1b multicenter, open-label, dose-escalation trial (NCT06961565) targeting symptomatic, inoperable, incompletely resected, or recurrent NF1-PN. This population represents the segment where current options are most constrained and where adult-specific evidence is absent. The Fast Track Designation supports rolling submission of the marketing application and positions PAS-004 for potential eligibility for accelerated approval or priority review, contingent on meeting relevant criteria at later development stages. The competitive context for NF1 drug development remains active. Selumetinib (AstraZeneca/Alexion) holds pediatric approval for inoperable NF1-PN, but no agent carries adult-specific approval in this indication. The macrocyclic MEK inhibitor class that PAS-004 represents has not previously produced an approved therapy in NF1, and the adult-focused trial design differentiates the program from the pediatric dataset that supported the selumetinib label. Whether the Phase I safety and disease control data from the advanced cancer study will translate to the NF1-PN population — a distinct tumor biology driven by NF1 loss-of-function rather than somatic oncogenic mutation — remains to be established in the dedicated NF1 trial. Your email address will not be published. Required fields are marked * Comment * Name * Email * Website